GW26-e2330 Efficacy and safety of 1-hour infusion of recombinant human atrial natriuretic peptide in patients with acute decompensated heart failure: a phase III, randomized, double-blind, placebo-controlled, multicenter trial

GW26-e2330 Efficacy and safety of 1-hour infusion of recombinant human atrial natriuretic peptide in patients with acute decompensated heart failure: a phase III, randomized, double-blind, placebo-controlled, multicenter trial

Objectives To evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP), in combination with standard therapy, in patients with acute decompensated heart failure (ADHF).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2015-10, Vol.66 (16), p.C208-C208
Hauptverfasser: Wang, Pengbo, Wang, Guo-Gan, Li, Yi-Shi, Liu, Wen-Xian, Bai, Shu-Gong, Zhen, Yang, Li, Dong-Ye, Yang, Ping, Hong, Lang, Sun, Jian-Hui, Chen, Jun-Zhu, Wang, Xian, Zhu, Ji-Hong, Yu, Li-Yian, Ye, Shao-Dong, Feng, Lei, Wang, Yang, Li, Wei, Luan, Xiao-Jun, Wang, Si-Jia
Format: Artikel
Sprache:eng
Schlagworte:
Cardiology
Cardiovascular
Confidence intervals
Heart failure
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives To evaluate the efficacy and safety of 1-h infusion of recombinant human atrial natriuretic peptide (rhANP), in combination with standard therapy, in patients with acute decompensated heart failure (ADHF).
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2015.06.796